Vulcan Value Partners LLC Grows Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

Vulcan Value Partners LLC raised its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 119.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 101,338 shares of the company's stock after purchasing an additional 55,237 shares during the quarter. Vulcan Value Partners LLC owned 0.33% of Medpace worth $33,668,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Pallas Capital Advisors LLC raised its position in Medpace by 179.7% in the 4th quarter. Pallas Capital Advisors LLC now owns 3,270 shares of the company's stock valued at $1,086,000 after buying an additional 2,101 shares during the last quarter. Barclays PLC grew its stake in shares of Medpace by 71.9% in the 3rd quarter. Barclays PLC now owns 19,781 shares of the company's stock worth $6,603,000 after acquiring an additional 8,275 shares in the last quarter. Sanctuary Advisors LLC raised its holdings in shares of Medpace by 20.5% in the fourth quarter. Sanctuary Advisors LLC now owns 4,964 shares of the company's stock valued at $1,738,000 after purchasing an additional 844 shares during the last quarter. SYM FINANCIAL Corp purchased a new stake in shares of Medpace in the fourth quarter valued at about $320,000. Finally, Tokio Marine Asset Management Co. Ltd. bought a new position in shares of Medpace during the fourth quarter valued at about $9,335,000. Institutional investors and hedge funds own 77.98% of the company's stock.

Insiders Place Their Bets

In other news, Director Fred B. Davenport, Jr. sold 1,712 shares of the firm's stock in a transaction that occurred on Thursday, April 24th. The shares were sold at an average price of $301.82, for a total value of $516,715.84. Following the completion of the transaction, the director now directly owns 2,998 shares in the company, valued at approximately $904,856.36. This trade represents a 36.35 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 20.30% of the stock is owned by corporate insiders.

Medpace Price Performance

Shares of MEDP traded down $2.24 during trading hours on Thursday, hitting $306.15. The company's stock had a trading volume of 202,455 shares, compared to its average volume of 341,125. The business has a 50 day simple moving average of $311.46 and a two-hundred day simple moving average of $330.93. Medpace Holdings, Inc. has a 52-week low of $250.05 and a 52-week high of $459.77. The company has a market cap of $8.80 billion, a price-to-earnings ratio of 24.27, a PEG ratio of 3.81 and a beta of 1.46.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its earnings results on Monday, April 21st. The company reported $3.67 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.06 by $0.61. The business had revenue of $558.57 million for the quarter, compared to analysts' expectations of $528.38 million. Medpace had a net margin of 19.17% and a return on equity of 51.48%. During the same quarter in the previous year, the firm posted $3.20 EPS. Research analysts predict that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have commented on MEDP. Leerink Partnrs upgraded shares of Medpace to a "hold" rating in a research note on Monday, March 24th. Robert W. Baird decreased their price target on Medpace from $340.00 to $313.00 and set a "neutral" rating for the company in a research report on Wednesday, April 23rd. William Blair reissued a "market perform" rating on shares of Medpace in a research report on Tuesday, April 22nd. TD Cowen lowered Medpace from a "buy" rating to a "hold" rating and decreased their target price for the company from $370.00 to $328.00 in a research report on Monday, April 14th. Finally, Truist Financial cut their price target on shares of Medpace from $333.00 to $300.00 and set a "hold" rating on the stock in a report on Wednesday, April 23rd. Eleven equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $349.30.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.